Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:ASMB
- CUSIP: 92282210
- Web: www.assemblybio.com
- Market Cap: $440.59 million
- Outstanding Shares: 17,346,000
- 50 Day Moving Avg: $23.63
- 200 Day Moving Avg: $19.19
- 52 Week Range: $4.88 - $28.18
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $684,369.00
- Price / Sales: 643.79
- Book Value: $3.92 per share
- Price / Book: 6.48
- EBIDTA: ($47,840,000.00)
- Return on Equity: -38.29%
- Return on Assets: -33.08%
- Current Ratio: 7.92%
- Quick Ratio: 7.92%
- Average Volume: 57,781 shs.
- Beta: 0.27
- Short Ratio: 4.55
Frequently Asked Questions for Assembly Biosciences (NASDAQ:ASMB)
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences Inc (NASDAQ:ASMB) posted its quarterly earnings results on Monday, November, 17th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.84. View Assembly Biosciences' Earnings History.
Who are some of Assembly Biosciences' key competitors?
Some companies that are related to Assembly Biosciences include TherapeuticsMD (TXMD), Retrophin (RTRX), Rockwell Medical (RMTI), Zogenix (ZGNX), Alimera Sciences (ALIM), Tonix Pharmaceuticals Holding Corp. (TNXP), Alliqua Biomedical (ALQA), Novogen Limited (NVGN), Immune Pharmaceuticals (IMNP), Echo Therapeutics (ECTE), Heron Therapeutics (HRTX), Kythera Biopharmaceuticals (KYTH) and ZS Pharma (ZSPH).
Who owns Assembly Biosciences stock?
Assembly Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include EcoR1 Capital LLC (17.05%), Jennison Associates LLC (11.67%), Perceptive Advisors LLC (3.85%), Vanguard Group Inc. (0.00%), Geode Capital Management LLC (0.00%) and Goldman Sachs Group Inc. (0.36%). View Institutional Ownership Trends for Assembly Biosciences.
Who sold Assembly Biosciences stock? Who is selling Assembly Biosciences stock?
Assembly Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Perceptive Advisors LLC, National Asset Management Inc. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Assembly Biosciences.
Who bought Assembly Biosciences stock? Who is buying Assembly Biosciences stock?
Assembly Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Vanguard Group Inc., Lyon Street Capital LLC, Laurion Capital Management LP, EAM Investors LLC, Geode Capital Management LLC, Victory Capital Management Inc. and Segantii Capital Management Ltd. View Insider Buying and Selling for Assembly Biosciences.
How do I buy Assembly Biosciences stock?
Shares of Assembly Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Assembly Biosciences stock cost?
One share of Assembly Biosciences stock can currently be purchased for approximately $25.40.
Consensus Ratings for Assembly Biosciences (NASDAQ:ASMB) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Assembly Biosciences (NASDAQ:ASMB)
(Data available from 5/25/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/19/2016||William Blair||Initiated Coverage||Market Perform -> Outperform||N/A|
Earnings History for Assembly Biosciences (NASDAQ:ASMB)Earnings History by Quarter for Assembly Biosciences (NASDAQ:ASMB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Assembly Biosciences (NASDAQ:ASMB)
2017 EPS Consensus Estimate: ($2.52)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Assembly Biosciences (NASDAQ:ASMB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Assembly Biosciences (NASDAQ:ASMB)
Insider Ownership Percentage: 15.90%Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Institutional Ownership Percentage: 64.82%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/11/2016||Derek A. Small||CEO||Buy||10,000||$5.53||$55,300.00|| |
|5/27/2014||Russell H Ellison||CEO||Buy||13,000||$0.92||$11,960.00|| |
|5/23/2014||David Jonathan Barrett||CFO||Buy||6,980||$0.86||$6,002.80|| |
|5/23/2014||Russell H Ellison||CEO||Buy||20,000||$0.91||$18,200.00|| |
|5/21/2014||Russell Ellison||CEO||Buy||10,000||$0.87||$8,700.00|| |
|5/20/2014||David Jonathan Barrett||CFO||Buy||40,000||$0.88||$35,200.00|| |
|2/5/2013||Russell H Ellison||CEO||Buy||15,000||$2.55||$38,250.00|| |
Headline Trends for Assembly Biosciences (NASDAQ:ASMB)
Latest Headlines for Assembly Biosciences (NASDAQ:ASMB)
| Assembly Biosciences Inc (ASMB) Given $16.00 Consensus Price Target by Analysts|
www.americanbankingnews.com - May 24 at 8:36 PM
|Assembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : May 11, 2017|
finance.yahoo.com - May 11 at 9:09 PM
|Brokers Issue Forecasts for Assembly Biosciences Inc's Q2 2017 Earnings (ASMB)|
www.americanbankingnews.com - May 11 at 9:16 AM
|Assembly Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : ASMB-US : May 9, 2017|
finance.yahoo.com - May 9 at 9:08 AM
|Brokerages Expect Assembly Biosciences Inc (ASMB) to Announce ($0.03) Earnings Per Share|
www.americanbankingnews.com - May 9 at 12:40 AM
|Assembly Biosciences (ASMB) Receives Daily Media Impact Rating of 0.20|
www.americanbankingnews.com - April 27 at 9:28 AM
|Analysts Anticipate Assembly Biosciences Inc (ASMB) to Post ($0.03) Earnings Per Share|
www.americanbankingnews.com - April 22 at 12:47 AM
|Assembly Biosciences (ASMB) Receives Daily News Impact Rating of 0.44|
www.americanbankingnews.com - April 20 at 8:29 AM
|Assembly Biosciences (ASMB) Earns Daily Coverage Optimism Score of -0.10|
www.americanbankingnews.com - April 14 at 1:08 PM
|Assembly Biosciences Inc (ASMB) Sees Large Decline in Short Interest|
www.americanbankingnews.com - April 13 at 12:14 AM
|Zacks: Assembly Biosciences Inc (ASMB) Given Average Recommendation of "Strong Buy" by Brokerages|
www.americanbankingnews.com - April 5 at 3:22 PM
|Zacks: Assembly Biosciences Inc (ASMB) Receives Average Recommendation of "" from Brokerages|
www.americanbankingnews.com - March 20 at 12:22 PM
|ASSEMBLY BIOSCIENCES, INC. Financials|
finance.yahoo.com - March 8 at 4:21 PM
|Assembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan|
finance.yahoo.com - February 21 at 9:10 AM
|Assembly Biosciences (ASMB) Completes Dose Ranging Portion of Phase 1a/1b Trial of ABI-H0731|
www.streetinsider.com - February 17 at 6:29 PM
|Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations|
finance.yahoo.com - February 16 at 8:34 AM
|Assembly Biosciences (ASMB) Looks Good: Stock Up 13.9%|
finance.yahoo.com - January 18 at 4:18 PM
|ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
us.rd.yahoo.com - January 10 at 8:43 PM
|8:11 am Assembly Biosciences enters into research, development, collaboration and license agreement with Allergan (AGN); Allergan to make upfront payment of $50 mln|
us.rd.yahoo.com - January 10 at 3:42 PM
|ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,|
biz.yahoo.com - January 10 at 3:42 PM
|Allergan (AGN) Enters Licensing Agreement with Assembly Biosciences (ASMB) to Obtain Worldwide Rights to GI Programs|
www.streetinsider.com - January 9 at 4:29 PM
|AGN Stock Is Preparing For Battle (AGN)|
www.investopedia.com - January 9 at 4:29 PM
|ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex|
biz.yahoo.com - December 9 at 8:43 PM
|ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - December 6 at 12:37 PM
|Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting|
finance.yahoo.com - November 11 at 12:59 PM
|Assembly Biosciences (ASMB) Commences ABI-H0731 Phase 1 as HBV Treatment|
www.streetinsider.com - November 10 at 2:05 PM
|Assembly Biosciences (ASMB) Worth a Look: Stock Up 7.3%|
www.zacks.com - October 17 at 8:26 AM
|Assembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea|
finance.yahoo.com - September 21 at 8:31 AM
|ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Other Events|
biz.yahoo.com - September 2 at 8:19 AM
|ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a|
biz.yahoo.com - June 6 at 4:02 PM
|ASSEMBLY BIOSCIENCES, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 11 at 4:04 PM
|Assembly Biosciences to Webcast Upcoming Investor Conferences - GlobeNewswire (press release)|
globenewswire.com - February 19 at 2:59 PM
|Assembly Biosciences to Webcast Upcoming Investor Conferences|
finance.yahoo.com - February 19 at 7:30 AM
Assembly Biosciences (ASMB) Chart for Thursday, May, 25, 2017